Nasal reactivity evaluation in children with allergic rhinitis receiving grass pollen sublingual immunotherapy
Background: The European Academy of Allergy and Clinical Immunology guidelines, strongly recommended allergen immunotherapy (AIT) as an effective treatment to achieve long-term clinical benefits and to modify the natural history of allergic diseases. Sublingual immunotherapy (SLIT) offers the possibility of home administration, which improves patient comfort and compliance. Objective: The primary outcome of this study was to assess the change in nasal reactivity after grass-pollen AIT treatment. Methods: This was a monocentric, prospective, observational study conducted in Rome from September 2016 to June 2018, in the Pediatric Department of Policlinico Umberto I. We enrolled children, ages between 6 and 12 years, with persistent allergic rhinitis (AR), sensitized to grass pollen. At the first visit (V0, September 2016), one group received the first dose of oral immunotherapy for grass-pollen spray buccal and the other group continued only standard therapy. All the patients had nasal specific immunoglobulin I (IgE) assay (Phl p1, Phl p5), active anterior rhinomanometry with a nasal provocation test (NPT), and spirometry. The patients attended two follow-up visits, in May 2017 (V1) and May 2018 (V2), with the same examinations as at V0. Results: During the treatment, we observed, in the treated group, a significant increase in the mean nasal flow compared with untreated children (p < 0.001). In the AIT group, we found an improvement of nasal function and only 21.05% of all the children in the active group with a positive NPT result at V2. In the control group, we found, at V2, a worsening of nasal function, with 89.47% of the children with a positive NPT result. Furthermore, we found a significant reduction of nasal specific IgE levels at the end of the observation period in the treated group. Conclusion: Analysis of our data provided evidence for a clinical effect of SLIT in inducing clinical changes and allergen tolerance in children with AR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Allergy and asthma proceedings - 41(2020), 5 vom: 01. Sept., Seite 357-362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schiavi, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
160227-82-7 |
|---|
| Anmerkungen: |
Date Completed 25.08.2021 Date Revised 25.08.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2500/aap.2020.41.200063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31440998X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31440998X | ||
| 003 | DE-627 | ||
| 005 | 20231225152652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2500/aap.2020.41.200063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM31440998X | ||
| 035 | |a (NLM)32867890 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schiavi, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nasal reactivity evaluation in children with allergic rhinitis receiving grass pollen sublingual immunotherapy |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2021 | ||
| 500 | |a Date Revised 25.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: The European Academy of Allergy and Clinical Immunology guidelines, strongly recommended allergen immunotherapy (AIT) as an effective treatment to achieve long-term clinical benefits and to modify the natural history of allergic diseases. Sublingual immunotherapy (SLIT) offers the possibility of home administration, which improves patient comfort and compliance. Objective: The primary outcome of this study was to assess the change in nasal reactivity after grass-pollen AIT treatment. Methods: This was a monocentric, prospective, observational study conducted in Rome from September 2016 to June 2018, in the Pediatric Department of Policlinico Umberto I. We enrolled children, ages between 6 and 12 years, with persistent allergic rhinitis (AR), sensitized to grass pollen. At the first visit (V0, September 2016), one group received the first dose of oral immunotherapy for grass-pollen spray buccal and the other group continued only standard therapy. All the patients had nasal specific immunoglobulin I (IgE) assay (Phl p1, Phl p5), active anterior rhinomanometry with a nasal provocation test (NPT), and spirometry. The patients attended two follow-up visits, in May 2017 (V1) and May 2018 (V2), with the same examinations as at V0. Results: During the treatment, we observed, in the treated group, a significant increase in the mean nasal flow compared with untreated children (p < 0.001). In the AIT group, we found an improvement of nasal function and only 21.05% of all the children in the active group with a positive NPT result at V2. In the control group, we found, at V2, a worsening of nasal function, with 89.47% of the children with a positive NPT result. Furthermore, we found a significant reduction of nasal specific IgE levels at the end of the observation period in the treated group. Conclusion: Analysis of our data provided evidence for a clinical effect of SLIT in inducing clinical changes and allergen tolerance in children with AR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Allergens |2 NLM | |
| 650 | 7 | |a Phl p V protein, Phleum pratense |2 NLM | |
| 650 | 7 | |a Plant Proteins |2 NLM | |
| 650 | 7 | |a PHLPI protein, Phleum pratense |2 NLM | |
| 650 | 7 | |a 160227-82-7 |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 700 | 1 | |a Brindisi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a De Castro, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a De Vittori, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Loffredo, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Spalice, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Duse, Marzia |e verfasserin |4 aut | |
| 700 | 1 | |a Zicari, Anna Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergy and asthma proceedings |d 1998 |g 41(2020), 5 vom: 01. Sept., Seite 357-362 |w (DE-627)NLM087622459 |x 1539-6304 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2020 |g number:5 |g day:01 |g month:09 |g pages:357-362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2500/aap.2020.41.200063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2020 |e 5 |b 01 |c 09 |h 357-362 | ||